Education and Empowerment Winona goes beyond prescriptions
Treatment protocols emphasize symptom management using prokinetic medications and nutritional support through small, frequent meal patterns
Jardiance may lead to modest weight loss, an average of 3% of body weight, but its unlikely to be as effective as semaglutide
weight loss (Phase 2/3 peak) | ~15% | ~22% | ~24% | | FDA Status | Approved (Wegovy, Ozempic) | Approved (Zepbound, Mounjaro) | Phase 3 (2026) | | Dosing frequency | Weekly | Weekly | Weekly | The additional glucagon receptor agonism is believed to be responsible for retatrutide's greater metabolic rate increase and enhanced fat oxidation compared to dual agonists
Brain 146 , 31923205 (2023)
Retatrutide is a next-generation GLP-1/GIP/GCGR agonist designed to support powerful, multi-pathway weight loss